Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSpyre Therapeutics Inc.

Spyre Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
108.755 USD 4.89 ( 4.71%)
Last update at 2026-11-09T17:50:00Z
VOLUME
394489
Market Cap
8019.40M

Momentum Score

…

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
104.41
Low
109.71
High
52 Week Price Range
14.51
Low
110.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
103.86
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-215.80M
Debt / Equity
0.16
ROE
-22.98%
Net Debt
-85.72M
ROCE
-30.53%
Diluted EPS TTM
-1.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -155.22M -207.97M -338.82M -83.95M -65.66M
Net income -155.20M -208.02M -338.79M -83.81M -65.80M
Selling general administrative 47.91M 45.78M 39.95M 28.53M 27.32M
Gross profit -171.65M 0.89M -0.08M - -
Reconciled depreciation 0.00M 0.00M 0.74M 1.57M 1.58M
Ebit -219.56M -128.56M -243.05M - -
Ebitda -209.56M -207.97M -242.30M - -
Depreciation and amortization 10.00M 0.96M 0.74M - -
Operating income -209.56M -208.57M -242.30M -84.78M -65.65M
Other operating expenses 209.56M 208.57M 243.19M - -
Tax provision -0.01M 0.05M -0.03M -0.14M 0.14M
Interest income 24.89M 21.31M 6.15M 0.84M 0.11M
Net interest income 24.89M 21.31M 6.15M 0.84M 0.11M
Income tax expense -0.01M 0.05M -0.03M - -
Total revenue 0.00M 0.89M 0.89M 2.33M 18.74M
Total operating expenses 37.91M 208.57M 243.19M 87.11M 84.39M
Cost of revenue 171.65M 0.96M 0.96M - -
Total other income expense net 54.34M 0.60M -96.51M -0.01M -0.12M
Net income from continuing ops -155.20M -208.02M -338.79M -83.81M -65.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 777.78M 608.48M 341.86M 71.14M 109.93M
Other current assets 21.25M 5.39M 2.25M 6.17M -
Total liab 62.55M 90.68M 157.84M 20.84M 25.98M
Total stockholder equity 715.24M 517.80M 184.02M 50.30M 83.94M
Other current liab 49.78M 53.39M 31.08M - 0.78M
Common stock 0.01M 0.01M 0.01M - -
Capital stock 155.84M 155.83M 184.94M 0.01M 0.01M
Retained earnings -1127.63M -972.43M -764.41M -425.62M -341.81M
Cash 85.72M 89.42M 188.89M 34.86M 15.14M
Total current liabilities 58.69M 54.06M 31.98M 14.66M 20.14M
Net debt -85.72M -89.42M -104.34M - -
Short long term debt total - 84.56M 84.56M - -
Other stockholder equity 1686.17M 1334.22M 763.19M - -
Total current assets 777.78M 608.47M 341.53M 62.26M 98.89M
Short term investments 670.81M 513.66M 150.38M 20.85M 77.99M
Net receivables - - - 0.38M -
Accounts payable 8.90M 0.67M 0.90M 0.68M 3.32M
Accumulated other comprehensive income 0.87M 0.18M 0.30M - -
Non currrent assets other - 0.01M 0.01M 2.24M 2.68M
Non current assets total 0.00M 0.01M 0.33M 8.89M 11.04M
Capital lease obligations - - 0.00M 4.63M 5.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -150.47M -353.29M -108.39M 57.01M -22.62M
Total cashflows from investing activities -143.47M -353.29M - - -
Net borrowings - 0.00M -0.02M - -
Total cash from financing activities 309.02M 410.91M 361.08M 42.68M 1.39M
Net income -155.20M -208.02M -338.79M -83.81M -65.80M
Change in cash -3.70M -99.79M 152.80M 19.44M -74.96M
Begin period cash flow 89.42M 189.22M 36.42M 16.98M 91.94M
End period cash flow 85.72M 89.42M 189.22M 36.42M 16.98M
Total cash from operating activities -169.25M -157.41M -99.91M -80.14M -53.72M
Issuance of capital stock 311.13M 405.23M 366.47M 42.87M 0.00M
Depreciation -8.09M 0.74M 0.74M 1.57M 1.58M
Other cashflows from investing activities 7.00M 15.47M - - -
Change to inventory - - -0.38M - -
Change to account receivables - 0.38M 0.38M - -
Other cashflows from financing activities -5.41M 174.52M 191.98M - -
Capital expenditures 0.00M 0.00M 0.00M 0.04M 0.57M
Change in working capital -5.93M -4.53M -5.21M -5.50M 1.83M
Stock based compensation 37.61M 44.83M 25.68M 7.11M 8.04M
Other non cash items -45.73M 10.31M 217.67M 0.40M 0.43M
Free cash flow -169.25M -157.41M -99.91M -80.18M -54.29M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SYRE
Spyre Therapeutics Inc.		 4.89
4.71%		 108.75 - - 650.22 8.38 1964.91 -7.96
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Building 23, Waltham, MA, United States, 02453

617 651 5940

https://www.spyre.com

125

Name Title Year Born
Dr. Cameron Turtle DPHIL, Ph.D. CEO & Director 1990
Mr. Scott L. Burrows Chief Financial Officer 1977
Ms. Heidy Abreu King-Jones J.D., L.L.M. Chief Legal Officer & Corporate Secretary 1983
Dr. Janet Gunzner-Toste M.B.A., Ph.D. Senior Vice President of Operations NA
Brian Connolly Chief Technical Officer NA
Mr. Eric McIntyre Vice President of Finance & Investor Relations NA
Mr. James Myers Vice President of Quality & Compliance NA
Dr. Kelly Boothe Ph.D. Senior Director of Corporate Communications & Investor Relations NA
Dr. Justin LaFountaine Ph.D. Senior Vice President of Corporate Development NA
Ms. Melissa Cooper Senior Vice President of People NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…